Exhalation Delivery System With Fluticasone Effective for Rhinosinusitis
26 Jan 2024
Clinical Result
FRIDAY, Jan. 26, 2024 -- For patients with chronic rhinosinusitis (CRS), an exhalation delivery system that delivers fluticasone (EDS-FLU) to sinonasal areas above the inferior turbinate is efficacious, irrespective of nasal polyps, according to a study published online Jan. 18 in the Journal of Allergy and Clinical Immunology: In Practice.
James N. Palmer, M.D., from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues examined EDS-FLU efficacy for CRS in two randomized, EDS-placebo-controlled trials in adults with CRS irrespective of polyps (ReOpen1; 332 patients) or exclusively without polyps (ReOpen2; 223 patients). For 24 weeks, patients received EDS-FLU one or two sprays/nostril or EDS-placebo twice daily.
The researchers found that the composite symptom score least-squares mean change for EDS-FLU one or two sprays/nostril versus EDS-placebo was −1.58 and −1.60 versus −0.62 in ReOpen1, and −1.54 and −1.74 versus −0.81 in ReOpen2. Sinus opacification least-squares mean change for one or two sprays/nostril of EDS-FLU versus EDS-placebo was −5.58 and −6.20 versus −1.60 in ReOpen1 and −7.00 and −5.14 versus +1.19 in ReOpen2. Compared with EDS-placebo, acute disease exacerbations were reduced by 56 to 66 percent with EDS-FLU. For patients using standard-delivery nasal steroid products just before entering the study, there were significant symptom reductions of a similar magnitude observed. Similar adverse events were seen to those with standard-delivery intranasal steroids.
"These findings provide strong evidence for an effective, noninvasive treatment option for people who continue to experience symptoms after over-the-counter medications have failed," Palmer said in a statement.
Several authors disclosed ties to pharmaceutical companies, including OptiNose US, which funded the study.
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.